Celularity - Class A opened higher at $0.77, compared with its previous close of $0.75. In the last trading session, the stock traded between $0.65 and $0.80. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Celularity - Class A is now worth
$ 0.94
Resulting in a loss of
$ 99.06 (99.06%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
$-0.07 (-9.45%)
Day High
$0.80
Day Low
$0.65
Day Open
$0.77
Prev Close
$0.75
Volume
1,17,939
1W Return
-15.84%
1M Return
-54.27%
3M Return
-4.23%
6M Return
-11.69%
1Y Return
-60.47%
Fundamentals
Market Cap ($ Mn)
22
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-154.53%
EPS (TTM)
$0.02
Investment Returns
1 Week
-15.84%
1 Month
-54.27%
3 Months
-4.23%
6 Months
-11.69%
9 Months
-45.60%
Financials
Quarterly
All values in $ Mn
11.4
Mar 25
5.7
Jun 25
5.3
Sep 25
4.1
Dec 25
3.8
Mar 26
5.4
Jun 26
Updates
30Sep
Celularity highlights Fontaine Vitale opening in Bali for Q1 2027
Fontaine Vitale in Bali targets Q1 2027 opening. First ASEAN facility to offer placenta-derived stem cell therapy. Developed by Genting Berhad with Celularity strategic input. Celularity to supply products from NJ cGMP facility.
1mo ago
30Sep
Celularity Q1 Results: EPS turns positive at $0.02, sales down 66%
Celularity reported Q1 EPS of $0.02, up 102.38% from $(0.84) last year. Sales fell 66.34% YoY to $3.846 million from $11.426 million. Company swung to positive EPS despite significant revenue contraction.
1mo ago
29Sep
Celularity names Naveen Jain to board of directors
Naveen Jain, founder of Viome, joins Celularity's Board of Directors. Appointment pending completion of Rule 14f-1 information statement process. Board now includes Hariri, Diamandis, Barach, with fifth director expected soon. Move aims to expand commercial reach of regenerative therapies.
Celularity regained compliance with Nasdaq minimum bid price rules. Company also met market value of listed securities requirements. Delinquent periodic filing deficiency remains unresolved. Listing status hinges on resolving the filing issue.
1mo ago
27Aug
Celularity stock up 131% on $300m MuseCell manufacturing deal
Celularity stock surged 131.72% to $2.04 on Thursday following the deal announcement. Partnership with MuseCell targets over $300 million in aggregate purchases over five years. Deal focuses on producing Dezawa MuseCells at Celularity's New Jersey facility. Collaboration expected to create more than 200 high-tech jobs in Florham Park.
2mo ago
26Aug
Celularity faces Nasdaq deadline over delayed Q1 and Q2 2026 filings
Celularity Inc. received a Nasdaq non-compliance notice on August 21, 2026. The issue stems from delayed Form 10-Q filings for Q1 and Q2 2026. A compliance plan must be submitted by September 4, 2026. Maximum compliance extension granted until November 16, 2026. Stock trading remains unaffected during this period.
